Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis YoY Growth in the U.S.: 77.0% in FY2025, up 14.0 pts from a year earlier.
Latest, FY2025
77.0%
Period ended Dec 31, 2025
Change on a year earlier
+14.0 pts
63.0% in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Kisqali | Oncology | HR+/HER2- metastatic breast cancer and early breast cancer | 2 975 | 77 | 1 808 | 33 | 33 | 4 783 | 58 | 57”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | YoY Growth in the U.S. (% USD / cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 77.0% | +14.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 63.0% | -56.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 119.0% | +80.0 pts | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 39.0% | +32.0 pts | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 7.0% | -20.0 pts | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 27.0% | -18.0 pts | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 45.0% | – | Novartis Form 6-K (0001370368-20-000007) ↗ |
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kisqali-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.